Investor mix
9 investors on record; lead investors include Primer Capital, Karista, GO CAPITAL, Newton Biocapital.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 5 | 56% |
| Private equity | 2 | 22% |
| Bank & private debt | 1 | 11% |
| Other / undisclosed | 1 | 11% |
Developing immunotherapeutics for treating ischemic stroke
9 investors on record; lead investors include Primer Capital, Karista, GO CAPITAL, Newton Biocapital.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 5 | 56% |
| Private equity | 2 | 22% |
| Bank & private debt | 1 | 11% |
| Other / undisclosed | 1 | 11% |